Where is cancer research headed in the next decade? Scientists and oncologists at the National Cancer Institute share their thoughts on the NEXT HORIZON IN PRECISION ONCOLOGY - proteogenomics.
News and Announcements
TGFβ is a cytokine with many, often paradoxical, roles in cancer biology. Acting as a tumor suppressor, TGFβ exerts negative control on epithelial cell proliferation - a function that tumor cells must overcome in order to progress to malignant disease. On the other hand, TGFβ also acts as a pro-...
March 25, 2021 | Read More
TGFβ is a cytokine with many, often paradoxical, roles in cancer biology. Acting as a tumor suppressor, TGFβ exerts negative control on epithelial cell proliferation - a function that tumor cells must overcome in order to progress to malignant disease. On the other hand, TGFβ also acts as a pro-...
March 25, 2021 | Read More
CPTAC researchers out of the University of Michigan have hit another home run. The Nesvizhskii lab, developer of the FragPipe proteomics pipeline, has developed an extension of its MSFragger flagship software to now identify N- and O-linked glycopeptides. The study was recently published in...
March 10, 2021 | Read More
Advancing Cancer Research Through Proteogenomics and Greater Collaboration
March 1, 2021 | Read More
Glioblastoma study could lead to new treatments, including better immunotherapies
February 22, 2021 | Read More
Prostate cancer screening is typically done by evaluation of levels of prostate-specific antigens (PSA). Unfortunately, its effectiveness in stratifying low risk patients from those with aggressive (AG)...
January 26, 2021 | Read More
Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer. A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. The...
January 7, 2021 | Read More
Activating point mutations in ErbB/Her2 receptor tyrosine kinases have an infamous role in promoting oncogenesis across several different cancers, including breast and lung. Heterodimer activation of the ErbB2/ErbB3 oncogenic unit induces cancer cell proliferation via PI3K/AKT signaling...
December 14, 2020 | Read More
In case you missed it, this final article (part 2 of 2) in the Investigator Spotlight Series, developed and written by Dr.
December 8, 2020 | Read More